Danish study links some hormonal contraceptives to rare brain tumor risk
A Danish study of ~3 million women over 25 years finds that certain hormonal contraceptives, especially injectable medroxyprogesterone (Depo-Provera), are linked to a higher risk of meningioma, a rare and usually benign brain tumor. The risk is greatest during active use and generally fades within five years after stopping; absolute risk remains small (about 5 of 1,000 lifetime, rising to ~6 per 1,000 for Depo-Provera users aged 25–44). Weaker associations are seen with combined oral contraceptives and mini-pills. The findings, published in JAMA Network Open, emphasize weighing benefits against rare risks and consulting doctors before changing methods; ongoing EMA investigations and FDA labeling reflect precautionary responses.
